DalsnaFinance

Colon cancer trial: Pfizer drug cuts risk of progression or death 56%

Stocks Stock Titan By Stock Titan 31 May 2026 12:00 1 min read
Colon cancer trial: Pfizer drug cuts risk of progression or death 56%

Colon cancer trial: Pfizer drug cuts risk of progression or death 56%  Stock Titan

Colon cancer trial: Pfizer drug cuts risk of progression or death 56% Stock Titan

Read the full story on Stock Titan → Opens the original article on news.google.com

Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.